Glucotrack, Inc. is focused on the design, development, and commercialization of technologies for people with diabetes. The Company is engaged in developing a long-term Implantable Continuous Blood Glucose Monitor (CBGM) for people living with Type 1 diabetes and insulin-dependent Type 2 diabetes. Its CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. Its CBGM technology allows for a less burdensome approach to glucose monitoring. It has also completed four animal studies with evolving prototype systems, all four of which consistently demonstrated a simple implant procedure, functionality, and safety. The Company has also demonstrated continuous glucose sensing in the epidural space via two additional animal trials, both of which demonstrated a simple implant procedure, functionality, and safety.
Ticker SymbolGCTK
Company nameGlucoTrack Inc
IPO dateApr 09, 2013
Founded at2010
CEOMr. Paul V. Goode, Ph.D.
Number of employees11
Security typeOrdinary Share
Fiscal year-endApr 09
Address301 Rt 17 North
CityRUTHERFORD
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code07070
Phone197286757878
Website
Ticker SymbolGCTK
IPO dateApr 09, 2013
Founded at2010
A total of
0.00
USD has been distributed in dividends over the past 5 years.

No Data